Corcept Therapeutics | CORT - Ebitda


Corcept Therapeutics reported $4.2M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Ardelyx USD 6.02M 447K Dec/2025
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
J&J USD 7.19B 2.32B Dec/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.84B 235M Sep/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 40.24M 1.53M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
TG Therapeutics USD 51.69M 19M Dec/2025